Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Arcturus Therapeutics (ARCT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, Arcturus Therapeutics Holdings Inc. (ARCT) could be a good stock pick from a technical perspective. ARCT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Arcturus Therapeutics Eyes Phase III CF Call, OTC Data as Vaccine Funds Pipeline
Arcturus Therapeutics NASDAQ: ARCT is positioning its mRNA platform around two rare-disease programs targeting cystic fibrosis and ornithine transcarbamylase deficiency, while its vaccine business is intended to help support therapeutic development, President and CEO Joseph Payne said during a Canaccord discussion.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to a loss of $0.34 per share a year ago.
Arcturus Therapeutics Q2 Earnings Call Highlights
Arcturus Therapeutics NASDAQ: ARCT reported progress across its rare-disease pipeline during the second quarter of 2026, completed enrollment and dosing in its Phase II ornithine transcarbamylase deficiency study, and regained global rights to its KOSTAIVE COVID-19 vaccine and self-amplifying mRNA platform following the end of its collaboration with CSL Seqirus.
Arcturus: Now That It's Come This Low, It's Time To Buy And Hold
Arcturus has dropped off enough to make it a net-cash stock - a stock trading for less its current asset value with all liabilities subtracted. A peer group of similar issues that I have rated here on Seeking Alpha has strongly outperformed the S&P 500 even through one of the strongest bull markets in history. This and the combination of a revenue generating asset portfolio and promising pipeline make Arcturus a compelling opportunity.
Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?
Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcturus could halve the grid's electrical losses using its nano-infused copper
The world uses a lot of copper, but thanks to the energy transition and data centers, it'll need a lot more. Between now and 2050, we'll have to produce more copper than has been mined throughout all of human history, according to one study.
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Shareholder/Analyst Call Prepared Remarks Transcript
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies
Arcturus Therapeutics NASDAQ: ARCT President and CEO Joseph Payne outlined the company's messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago.
